Literature DB >> 9758899

Human eotaxin induces eosinophil-derived neurotoxin release from normal human eosinophils.

A El-Shazly1, K Masuyama, K Nakano, M Eura, Y Samejima, T Ishikawa.   

Abstract

BACKGROUND: Eosinophil granule proteins deposition at the site of allergic inflammation contributes to the late-phase reaction of hypersensitivity diseases. In the present communication, we describe the effect of human eotaxin on normal human eosinophil exocytosis measured as degranulation of eosinophil-derived neurotoxin (EDN).
METHODS: Purified eosinophils were obtained from normal healthy volunteers with the CD16-negative procedure. Purified eosinophils were stimulated with various concentrations of eotaxin and the amount of EDN released was analysed by radioimmunoassay. Flow cytometry was used to examine the surface expression of adhesion molecules on eosinophils.
RESULTS: Eotaxin significantly induced EDN release in a dose-dependent manner. The potency of eotaxin in this effect was equal to that of RANTES, and comparable to that of platelet-activating factor. Eotaxin-induced EDN release was blocked by cytochalasin B in a dose-dependent manner. The surface expression of CD11a, CD11b, CD18 and VLA-4 adhesion molecules on normal human eosinophils were not modulated by eotaxin stimulation.
CONCLUSIONS: These results indicate that eotaxin may play an important role not only as a selective chemotaxin for the cell type but also as a secretagogue. Furthermore, they demonstrate a degranulation mechanism(s) involving cytoskeletal changes which is probably independent of the quantitative expression of adhesion molecules.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9758899     DOI: 10.1159/000053573

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  8 in total

1.  CCL11 elicits secretion of RNases from mouse eosinophils and their cell-free granules.

Authors:  Revital Shamri; Rossana C N Melo; Kristen M Young; Maytal Bivas-Benita; Jason J Xenakis; Lisa A Spencer; Peter F Weller
Journal:  FASEB J       Date:  2012-01-31       Impact factor: 5.191

2.  PI3K, ERK, p38 MAPK and integrins regulate CCR3-mediated secretion of mouse and human eosinophil-associated RNases.

Authors:  R Shamri; K M Young; P F Weller
Journal:  Allergy       Date:  2013-06-06       Impact factor: 13.146

Review 3.  Eotaxin-1 (CCL11) in neuroinflammatory disorders and possible role in COVID-19 neurologic complications.

Authors:  Donya Nazarinia; Mahin Behzadifard; Javad Gholampour; Roqaye Karimi; Mohammadali Gholampour
Journal:  Acta Neurol Belg       Date:  2022-06-12       Impact factor: 2.471

4.  Novel co-operation between eotaxin and substance-P in inducing eosinophil-derived neurotoxin release.

Authors:  A El-Shazly; T Ishikawa
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

Review 5.  Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity.

Authors:  Francis Davoine; Paige Lacy
Journal:  Front Immunol       Date:  2014-11-10       Impact factor: 7.561

6.  Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody.

Authors:  Simon Gebremeskel; Julia Schanin; Krysta M Coyle; Melina Butuci; Thuy Luu; Emily C Brock; Alan Xu; Alan Wong; John Leung; Wouter Korver; Ryan D Morin; Robert P Schleimer; Bruce S Bochner; Bradford A Youngblood
Journal:  Front Immunol       Date:  2021-03-10       Impact factor: 7.561

Review 7.  Recent advances of eosinophils and its correlated diseases.

Authors:  Zhang Tao; Hua Zhu; Jiateng Zhang; Zhiming Huang; Ze Xiang; Tu Hong
Journal:  Front Public Health       Date:  2022-07-25

8.  Human eosinophil adhesion and degranulation stimulated with eotaxin and RANTES in vitro: lack of interaction with nitric oxide.

Authors:  Letícia Lintomen; Gilberto Franchi; Alexandre Nowill; Antonio Condino-Neto; Gilberto de Nucci; Angelina Zanesco; Edson Antunes
Journal:  BMC Pulm Med       Date:  2008-08-12       Impact factor: 3.317

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.